These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 20553195)

  • 1. Hematologic toxicity in patients treated with sunitinib for advanced thyroid cancer.
    Gkountouvas A; Kostoglou-Athanassiou I; Veniou E; Repousis P; Ziras N; Kaldrimidis P
    Thyroid; 2010 Jun; 20(6):597-600. PubMed ID: 20553195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.
    Carr LL; Mankoff DA; Goulart BH; Eaton KD; Capell PT; Kell EM; Bauman JE; Martins RG
    Clin Cancer Res; 2010 Nov; 16(21):5260-8. PubMed ID: 20847059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case of advanced medullary thyroid carcinoma successfully treated with sunitinib.
    Bugalho MJ; Domingues R; Borges A
    Oncologist; 2009 Nov; 14(11):1083-7. PubMed ID: 19887470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.
    Cabanillas ME; Waguespack SG; Bronstein Y; Williams MD; Feng L; Hernandez M; Lopez A; Sherman SI; Busaidy NL
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2588-95. PubMed ID: 20392874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surufatinib in Chinese Patients with Locally Advanced or Metastatic Differentiated Thyroid Cancer and Medullary Thyroid Cancer: A Multicenter, Open-Label, Phase II Trial.
    Chen J; Ji Q; Bai C; Zheng X; Zhang Y; Shi F; Li X; Tang P; Xu Z; Huang R; Huang T; Pan Y; Fan S; Zhou J; Su W
    Thyroid; 2020 Sep; 30(9):1245-1253. PubMed ID: 32075524
    [No Abstract]   [Full Text] [Related]  

  • 6. Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis.
    Funakoshi T; Latif A; Galsky MD
    Cancer Treat Rev; 2013 Nov; 39(7):818-30. PubMed ID: 23455076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic cooperation between sunitinib and cisplatin promotes apoptotic cell death in human medullary thyroid cancer.
    Lopergolo A; Nicolini V; Favini E; Dal Bo L; Tortoreto M; Cominetti D; Folini M; Perego P; Castiglioni V; Scanziani E; Borrello MG; Zaffaroni N; Cassinelli G; Lanzi C
    J Clin Endocrinol Metab; 2014 Feb; 99(2):498-509. PubMed ID: 24276455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity and safety of sunitinib in patients with advanced radioactive iodine-refractory differentiated thyroid carcinoma in clinical practice.
    Díez JJ; Iglesias P; Alonso T; Grande E
    Endocrine; 2015 Mar; 48(2):582-8. PubMed ID: 25030550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review.
    Maghsoomi Z; Emami Z; Malboosbaf R; Malek M; Khamseh ME
    BMC Cancer; 2021 May; 21(1):579. PubMed ID: 34016077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 2 clinical trial of sunitinib as adjunctive treatment in patients with advanced differentiated thyroid cancer.
    Bikas A; Kundra P; Desale S; Mete M; O'Keefe K; Clark BG; Wray L; Gandhi R; Barett C; Jelinek JS; Wexler JA; Wartofsky L; Burman KD
    Eur J Endocrinol; 2016 Mar; 174(3):373-80. PubMed ID: 26671977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma.
    Rini BI; Choueiri TK; Elson P; Khasawneh MK; Cotta C; Unnithan J; Wood L; Mekhail T; Garcia J; Dreicer R; Bukowski RM
    Cancer; 2008 Sep; 113(6):1309-14. PubMed ID: 18618496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer.
    Blevins DP; Dadu R; Hu M; Baik C; Balachandran D; Ross W; Gunn B; Cabanillas ME
    Thyroid; 2014 May; 24(5):918-22. PubMed ID: 24635127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.
    Schlumberger MJ; Elisei R; Bastholt L; Wirth LJ; Martins RG; Locati LD; Jarzab B; Pacini F; Daumerie C; Droz JP; Eschenberg MJ; Sun YN; Juan T; Stepan DE; Sherman SI
    J Clin Oncol; 2009 Aug; 27(23):3794-801. PubMed ID: 19564535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three cases of sporadic medullary thyroid carcinoma in progression treated with sunitinib.
    Currás Freixes M; Díaz Pérez JÁ; Casado Herráez A; Ochagavía Cámara S
    Endocrinol Nutr; 2014 Jan; 61(1):62-3. PubMed ID: 24125629
    [No Abstract]   [Full Text] [Related]  

  • 15. A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study.
    Ravaud A; de la Fouchardière C; Caron P; Doussau A; Do Cao C; Asselineau J; Rodien P; Pouessel D; Nicolli-Sire P; Klein M; Bournaud-Salinas C; Wemeau JL; Gimbert A; Picat MQ; Pedenon D; Digue L; Daste A; Catargi B; Delord JP
    Eur J Cancer; 2017 May; 76():110-117. PubMed ID: 28301826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth.
    Strock CJ; Park JI; Rosen M; Dionne C; Ruggeri B; Jones-Bolin S; Denmeade SR; Ball DW; Nelkin BD
    Cancer Res; 2003 Sep; 63(17):5559-63. PubMed ID: 14500395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of Patients with Locally Advanced Metastatic Medullary Thyroid Cancer and Induction Therapy with Tyrosine Kinase Inhibitors in Slovenia.
    Grasic Kuhar C; Lozar T; Besic N; Music Marolt M
    Adv Ther; 2021 Dec; 38(12):5684-5699. PubMed ID: 34674146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The placebo effect in thyroid cancer: a meta-analysis.
    Llavero-Valero M; Guillén-Grima F; Zafon C; Galofré JC
    Eur J Endocrinol; 2016 Apr; 174(4):465-72. PubMed ID: 26764417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma.
    de Groot JW; Zonnenberg BA; van Ufford-Mannesse PQ; de Vries MM; Links TP; Lips CJ; Voest EE
    J Clin Endocrinol Metab; 2007 Sep; 92(9):3466-9. PubMed ID: 17579194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant treatment of unresectable medullary thyroid cancer with sunitinib.
    Cleary JM; Sadow PM; Randolph GW; Palmer EL; Lynch TP; Nikiforov YE; Wirth LJ
    J Clin Oncol; 2010 Aug; 28(23):e390-2. PubMed ID: 20567012
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.